Evidence map›Paper›PMID 30944164›Full record

Trial reportScience translational medicine2019

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.

Claire D Bourke, Ethan K Gough, Godfrey Pimundu, Annie Shonhai, Chipo Berejena, Louise Terry, Lucas Baumard, Naheed Choudhry, Yusuf Karmali, Mutsa Bwakura-Dangarembizi and 16 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Adjunct Therapy for CD4Frontiers in immunology · 2021
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Immunomodulatory effect of propolisOpen veterinary journal · 2024
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 4 countries.

Claire D BourkeBlizard Institute, Queen Mary University of London, London E1 2AT, UK. c.bourke@qmul.ac.uk.ORCID 0000-0002-7244-0895
Ethan K GoughSchool of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0001-5265-7731
Godfrey PimunduJoint Clinical Research Centre, Kampala, Uganda.
Annie ShonhaiCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID 0000-0001-7414-3301
Chipo BerejenaCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Louise TerryRoyal London Hospital, Barts Health NHS Trust, London E1 1BB, UK.
Lucas BaumardBlizard Institute, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0003-1496-0152
Naheed ChoudhryBlizard Institute, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0001-6386-9908
Yusuf KarmaliBlizard Institute, Queen Mary University of London, London E1 2AT, UK.
Mutsa Bwakura-DangarembiziCollege of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID 0000-0001-7751-6177
Victor MusiimeJoint Clinical Research Centre, Kampala, Uganda.ORCID 0000-0001-7472-9054
Joseph LutaakomeUganda Virus Research Institute/MRC Uganda Research Unit on AIDS, Entebbe, Uganda.
Adeodata KekitiinwaBaylor College of Medicine Children's Foundation-Uganda, Mulago Hospital, Kampala, Uganda.
Kuda MutasaZvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
Alexander J SzubertMRC Clinical Trials Unit at University College London, London WC1V 6LJ, UK.ORCID 0000-0002-2082-0861
Moira J SpyerMRC Clinical Trials Unit at University College London, London WC1V 6LJ, UK.ORCID 0000-0001-9149-6029
Jane R DeaytonBlizard Institute, Queen Mary University of London, London E1 2AT, UK.
Magdalena GlassSchool of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Hyun Min GeumSchool of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Claire PardieuBlizard Institute, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0003-4257-3811
Diana M GibbMRC Clinical Trials Unit at University College London, London WC1V 6LJ, UK.ORCID 0000-0002-9738-5490
Nigel KleinUCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.ORCID 0000-0003-3925-9258
Thaddeus J EdensDevil's Staircase Consulting, West Vancouver, British Columbia V7T 1V7, Canada.
A Sarah WalkerMRC Clinical Trials Unit at University College London, London WC1V 6LJ, UK.
Amee R MangesSchool of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0003-2462-7249
Andrew J PrendergastBlizard Institute, Queen Mary University of London, London E1 2AT, UK.
Queen Mary University of London · GBMRC Clinical Trials Unit at UCL · GBUniversity of British Columbia · CAUniversity of Zimbabwe · ZWJoint Clinical Research Centre · UG3v Geomatics (Canada) · CABarts Health NHS Trust · GBBaylor College of Medicine Children’s Foundation · UGGreat Ormond Street Hospital · GBUganda Virus Research Institute · UGZvitambo Institute for Maternal and Child Health Research · ZW

Funding

CIHRCIHR G0300400Medical Research Council G0300400Medical Research Council G1001190Medical Research Council MC_EX_G0300400Medical Research Council MC_U122886353Medical Research Council MC_UU_12023/17Medical Research Council MC_UU_12023/26Wellcome Trust 093768Wellcome Trust 093768/Z/10/ZWellcome Trust 108065Wellcome Trust 108065/Z/15/ZWellcome Trust 206225Wellcome Trust 206225/Z/17/Z
6 · The paper itself

Abstract

Long-term cotrimoxazole prophylaxis reduces mortality and morbidity in HIV infection, but the mechanisms underlying these clinical benefits are unclear. Here, we investigate the impact of cotrimoxazole on systemic inflammation, an independent driver of HIV mortality. In HIV-positive Ugandan and Zimbabwean children receiving antiretroviral therapy, we show that plasma inflammatory markers were lower after randomization to continue (

Indexed as

Gastrointestinal MicrobiomeCD4-Positive T-LymphocytesChildChild, PreschoolCytokinesDisease ProgressionEpithelial CellsHIV InfectionsHumansInflammationInflammation MediatorsIntestinesNutritional StatusPhenotypeStreptococcusTrimethoprim, Sulfamethoxazole Drug CombinationCytokinesInflammation MediatorsTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID30944164
PMCPMC6783302
OpenAlexW2932604041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.